Vistagen Therapeutics, Inc. (VTGN)

Market Cap	70.61M
Revenue (ttm)	876,000
Net Income (ttm)	-39.57M
Shares Out	27.06M
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,117
Open	2.670
Previous Close	2.670
Day's Range	2.520 - 2.670
52-Week Range	2.520 - 5.860
Beta	0.78
Analysts	Strong Buy
Price Target	15.00 (+474.71%)
Earnings Date	Nov 7, 2024

About VTGN

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Analyst Forecast

According to one analyst, the rating for VTGN stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target

$15.0

(474.71% upside)

Analyst Consensus: Strong Buy